We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$115M
AUM Growth
+$35.6M
Cap. Flow
+$33.1M
Cap. Flow %
28.7%
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.39M
2
INDA icon
iShares MSCI India ETF
INDA
+$872K
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$767K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$708K
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$648K

Top Sells

Rank Stock Value
1
UPW icon
ProShares Ultra Utilities
UPW
+$1.11M
2
VDE icon
Vanguard Energy ETF
VDE
+$755K
3
RXDX
Ignyta, Inc.
RXDX
+$612K
4
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$430K
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$359K

Sector Composition

Rank Sector Weight
1 Healthcare 78.8%
2 Financials 0.81%
3 Technology 0.51%
4 Consumer Discretionary 0.44%
5 Communication Services 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
76
DELISTED
Audentes Therapeutics, Inc
BOLD
$785K 0.68%
26,118
+14,220
+120% +$481K
IONS icon
77
Ionis Pharmaceuticals
IONS
$9.35B
$775K 0.67%
17,582
-1,028
-6% -$52.2K
BIIB icon
78
Biogen
BIIB
$29.9B
$774K 0.67%
2,826
-164
-5% -$50.9K
LXRX icon
79
Lexicon Pharmaceuticals
LXRX
$1.02B
$770K 0.67%
89,845
-5,234
-6% -$48.4K
SAGE
80
DELISTED
Sage Therapeutics
SAGE
$768K 0.67%
4,771
+2,584
+118% +$439K
EXEL icon
81
Exelixis
EXEL
$13.9B
$764K 0.66%
34,479
-2,043
-6% -$56.5K
ATNX
82
DELISTED
Athenex, Inc. Common Stock
ATNX
$759K 0.66%
2,230
+1,183
+113% +$375K
CBIO
83
Crescent Biopharma
CBIO
$602M
$755K 0.66%
465
+255
+121% +$530K
RIGL icon
84
Rigel Pharmaceuticals
RIGL
$680M
$754K 0.65%
21,288
+11,415
+116% +$457K
UTHR icon
85
United Therapeutics
UTHR
$26.3B
$754K 0.65%
6,708
-390
-5% -$49.5K
PRTA icon
86
Prothena Corp
PRTA
$458M
$751K 0.65%
20,456
+10,904
+114% +$397K
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
$745K 0.65%
14,103
-826
-6% -$48.2K
CELG
88
DELISTED
Celgene Corp
CELG
$742K 0.64%
8,314
-491
-6% -$47.1K
BCRX icon
89
BioCryst Pharmaceuticals
BCRX
$2.37B
$735K 0.64%
154,147
+83,066
+117% +$427K
TVRD
90
Tvardi Therapeutics
TVRD
$23.5M
$735K 0.64%
1,649
+881
+115% +$427K
ALNY icon
91
Alnylam Pharmaceuticals
ALNY
$36.3B
$721K 0.63%
6,052
+3,277
+118% +$422K
BLUE
92
DELISTED
bluebird bio
BLUE
$709K 0.62%
321
+171
+114% +$435K
ACGN
93
DELISTED
Aceragen Inc
ACGN
$708K 0.61%
2,833
+1,506
+113% +$413K
AIMT
94
DELISTED
Aimmune Therapeutics
AIMT
$703K 0.61%
22,101
+11,765
+114% +$414K
TCRT icon
95
Alaunos Therapeutics
TCRT
$4.74M
$695K 0.6%
1,183
+638
+117% +$398K
ABEO icon
96
Abeona Therapeutics
ABEO
$345M
$677K 0.59%
1,886
+1,012
+116% +$376K
CYTK icon
97
Cytokinetics
CYTK
$11B
$672K 0.58%
93,309
+50,664
+119% +$434K
LUMO
98
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$656K 0.57%
10,061
+5,453
+118% +$386K
TSRO
99
DELISTED
TESARO, Inc.
TSRO
$651K 0.56%
11,391
-632
-5% -$40.7K
DOVA
100
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$630K 0.55%
23,227
+12,183
+110% +$364K
2 3
4
5 6

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.

  • Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
  • Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
  • Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
  • Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
  • Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.

Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.